Current Topics in Medicinal Chemistry - Volume 25, Issue 22, 2025

Healthcare organizations are complicated and demanding for all stakeholders, but artificial intelligence (AI) has revolutionized several sectors, especially healthcare, with the potential to enhance patient outcomes and standard of life. Quick advancements in AI can transform healthcare by implementing it into clinical procedures. Reporting AI's involvement in clinical settings is vital for its successful adoption by providing medical professionals with the necessary information and tools.

This paper offers a thorough and up-to-date summary of the present condition of AI in medical settings, including its possible uses in patient interaction, treatment suggestions, and disease diagnosis. It also addresses the challenges and limitations, including the necessity for human expertise along with future directions. In doing so, it improves the understanding of AI's relevance in healthcare and supports medical institutions in successfully implementing AI technologies.

The structured literature review, with its dependable and reproducible research process, allowed the authors to acquire 337 peer-reviewed publications from indexing databases, such as Scopus and EMBASE, without any time restrictions. The researchers utilized both qualitative and quantitative factors to assess authors, publications, keywords, and collaboration networks.

AI implementation in healthcare holds enormous potential for enhancing patient outcomes, treatment recommendations, and disease diagnosis. AI technologies can use massive datasets and recognize patterns to beat human performance in various healthcare domains. AI provides improved accuracy, reduced expenses, and time savings. It can transform customized medicine, optimize drug dosages, improve management of population health, set guidelines, offer digital medical assistants, promote mental health services, boost patient knowledge, and maintain patient-clinician trust.

AI can be utilized to detect diseases, develop customized therapy plans, and support medical professionals with their clinical decision-making. Instead of just automating jobs, AI focuses on creating technologies that can improve patient care in several healthcare settings. However, challenges such as biasness, data confidentiality, and data quality must be resolved for the appropriate and successful integration of AI in healthcare.

Prostate and pancreatic cancers pose significant global health challenges. This study explored the potential of compound 5b, a novel phthalimido-1,3-thiazole derivative, as an anticancer agent against these malignancies.

In vitro, compound 5b exhibited potent cytotoxic activity against both prostate (DU-145 and PC-3) and pancreatic (Panc-1 and Mia Paca-2) cancer cell lines. Notably, it significantly reduced colony formation in PC-3 cells, potentially hindering tumor growth. Furthermore, treatment with compound 5b suppressed cell migration and induced cell cycle arrest in the PC-3 line. Additionally, it triggered cell death through late apoptosis and necrosis at higher concentrations. Safety evaluations in mice revealed no mortality or adverse effects after a 30-day treatment with compound 5b. Key blood parameters (hematology) and biochemical markers of liver and kidney function remained unaltered.

Compound 5b significantly reduced colony formation, suppressed cell migration, and induced cell cycle arrest and apoptosis/necrosis in prostate cancer cells. In vivo, safety evaluations showed no adverse effects in treated mice, with blood and biochemical markers remaining normal.

These findings suggest that compound 5b holds promise for further development as a therapeutic option for prostate and pancreatic cancers. Its multimodal activity profile, targeting cell viability, migration, cell cycle progression, and cell death, warrants further investigation.

To investigate the antimicrobial potential of methanol fruit extract of Solanum xanthocarpum against Methicillin-Resistant Staphylococcus aureus (MRSA) and elucidate its mode of action.

The rise of antimicrobial resistance (AMR) demands the exploration of alternative therapeutic strategies to combat resistant pathogens.

To evaluate the efficacy of Solanum xanthocarpum methanol extract against MRSA, and identify its active constituents and mechanism of action.

The fruits of Solanum xanthocarpum were extracted using various solvents, with hexane and methanol yielding the highest results. Microbroth dilution assays assessed antimicrobial activity, while in vitro assays such as Alamar blue, Scanning Electron Microscopy (SEM), protein, and nucleic acid leakage examined metabolic disruption and cell membrane integrity. Gas Chromatography-Mass Spectrometry (GC-MS) was used to identify active compounds, and molecular docking studies assessed interactions with key MRSA proteins.

The methanol extract demonstrated significant antimicrobial activity against MRSA, causing metabolic disruption and leakage of cellular contents as evidenced by various in vitro assays including alarm blue, SEM, and protein and nucleic acid leakage assay. GC-MS analysis identified alpha-linoleic acid and palmitic acid as key active components. Molecular docking studies confirmed their inhibition of beta-lactamase activity, cell wall biosynthesis, efflux pumps, and virulence factors.

The findings suggest that Solanum xanthocarpum methanol fruit extract has promising potential as a natural remedy against AMR associated with MRSA.